Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition

REPLIGEN CORP

2024-Q2 EPS reported $0.10 revenue$305,419,000

Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.
Book-to-bill 1.02 for quarter; orders $157M; new modalities sales up 5% YoY.
CEO Tony Hunt becomes Executive Chair; Olivier Loeillot appointed President & CEO effective Sept 1.
Post-quarter-end, entered agreement to acquire chromatography innovator Tantti Laboratory Inc. (value undisclosed).
FY 2024 revenue guidance narrowed to $620-635M; adjusted EPS guidance unchanged at $1.42-1.49.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.